drugset

drugset / Trial / NCT00111774

Evaluating ABX-EGF in Patients With Metastatic ColorectalCarcinoma

NCT00111774 ↗

Phase 2 Completed 150 enrolled Amgen

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine if ABX-EGF is safe and efficacious in patients with metastatic colorectal cancer.

Timeline

Start: 2002-03
Primary completion: —
Completion: —

Publications

Results Hecht JR, Patnaik A, Berlin J, Venook A, Malik I, Tchekmedyian S, Navale L, Amado RG, Meropol NJ. Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer. Cancer. 2007 Sep 1;110(5):980-8. doi: 10.1002/cncr.22915.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Panitumumab	Monoclonal antibody	2.5 mg/kg	Intravenous

Indications